Clinical safety profile of Premi-Rab a new indigenous equine rabies immunoglobulin for cat III animal bite victims at anti rabies clinic of a tertiary care hospital, Karnataka

Jahnavi Rajagopal, Mythily M. R., Harish B. R., Padmaja Swamy


  • Background: WHO guidelines recommend for treating Cat III animal bite victims with local infiltration of Equine Rabies Immunoglobulin (ERIG) into and around animal bite wounds followed by anti-rabies vaccine (ARV).The main reason for non-use of ERIGs by medical profession is the fear of anaphylaxis and laborious process. The present study was taken up with the objectives to assess the clinical safety of a new ERIG, describe sociodemographic profile of ERIG recipients and compliance to Intra Dermal Rabies Vaccine (IDRV), who reported to Anti Rabies Clinic (ARC) of Mandya Institute of Medical Sciences (MIMS), Mandya.

    Methods: Descriptive study at ARC, MIMS, Mandya for a period of one year. The data was collected using structured questionnaire. The data was entered into Microsoft excel and results were expressed using descriptive statistics.

    Results: The study revealed that cat III animal bite victims were 3400 (56.3%), of these only 545 (16.0%) opted for the new ERIG. Skin Sensitivity Test (SST) showed positive results in 17 (3.1%) cases. Among the ERIG recipients 28 (5.1%) had mild adverse reaction to ERIG. The compliance rate was 49.2% for all 4 doses of IDRV.

    Conclusions: 3.1% showed positive result to SST. 5.1% had mild adverse reaction to ERIG.


Safety profile, New equine rabies immunoglobulin, Category III animal bite, Compliance to IDRV

Full Text:



World Health Organization. Rabies vaccines: WHO position paper, Weekly Epidemiological Record, No. 32. 2010;85:309-20.

World Health Organization‎. WHO Expert Consultation on Rabies: second report. World Health Organization, 2013. Available at: Accessed on 20 November 2018.

Sudarshan MK, Madhusudhana SN, Mahendra BJ, Rao NS, AshwathNaryana DH, Abdul RS, et al. Assessing the burden of Human rabies in India: Results of a National Multi-center epidemiological survey. Int J Infect Dis. 2007;11:29-35.

Sudarshan MK, Mahendra BJ, Madhusudhana SN, AshwathNaryana DH, Abdul RS, Rao NS, et al. An epidemiological study of animal bites in India: results of a WHO sponsored national multi-centric rabies survey. J Commun Dis. 2006;38(1):32-9.

World Health organization. WHO expert consultation on rabies. Technical report series 982. WHO Geneva, 2013.

Ravish HS, Rupsa B, Ashwath Narayana DH, Rachana AR. Safety of equine rabies immunoglobulin in children. APCRI J. 2014;16(1):7-9.

Tapas RB, Durga MS, Ashwini KP. Safety of equine rabies immunoglobulin injection into fingers and toes. Asian Biomedicine. 2012;6(3):429-32.

Satpathy DM, Sahu T, Behera TR. Equine rabies immunoglobulin: a study on its clinical safety. J Indian Med Assoc. 2005;103(4):241-2.

Chawan VS, Tripathi RK, Sankhe L, Fernandes AC, Daftary GV. Safety of equine rabies immunoglobulin in grade III bites. Indian J Community Med. 2007;32:73-4.

Vinay M, Mahendra BJ, Nagaraj Goud B, Asha Bullappa, Ananthachari KR, Sheethal MP. Socio-demographic characteristics affecting compliance to intra dermal rabies vaccination at anti rabies clinic in a Government tertiary care hospital in Karnataka. J Evolution Med Dental Sci. 2013;2(37):7092-7.

Shankaraiah RH, Rajashekar RA, Veena V, Hanumanthaiah AN. Compliance to anti-rabies vaccination in post-exposure prophylaxis. Indian J Public Health. 2015;59:58-60.